VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

"The medication's going to be 50 percent of your journey, and the other 50 percent is still what you choose to eat and the ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

The 61-year-old man received a new kidney from a deceased donor after being diagnosed with “nephrosclerosis-related end-stage ...

Question: I am a woman with a BMI of 31 and have recently been put on statins for high cholesterol. I have also been told ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...